Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.
The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.
≥ 18 years of age [+7]
Patients who have had systemic anticancer therapy, including any investigational... [+5]
Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors. The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the recommended dose and the safety and tolerability of ADCE-T02 when given as a single therapy over a range of different dose levels. The expansion phase is now open for enrollment in indications including HNSCC and PDAC.
Patients must have pathologically confirmed unresectable advanced solid tumor [+7]
Prior treatment with any agent targeting Tissue Factor or any ADC with a topoiso... [+9]
The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the Recommended Expansion Dose and the safety and tolerability of ADCE-B05 when given as a single therapy over a range of different dose levels.
Histologically or cytologically confirmed diagnosis of solid tumor [+7]
Treatment with systemic anticancer therapy, including any investigational agent... [+10]
